Tern raises £420,000 through Placing, to invest in portfolio companies

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that it has raised £420,000, before expenses, through a placing of 17,500,000 new ordinary shares of 0.02p each in the Company at a price of 2.4 pence per new Ordinary Share. The Placing is conditional upon the Placing Shares being admitted to trading on AIM.

The Placing Shares will represent approximately 4.1 per cent. of the Company’s enlarged issued share capital following the Placing.  The Issue Price represents a discount of approximately 30.4 per cent. to the mid-market closing price of 3.45 pence per Ordinary Share on 11 April 2024, being the latest practicable business day prior to the publication of this announcement.

The net proceeds of the Placing will be used to provide the Company with funds to invest in Wyld Networks, through the exercise of warrants held by the Company, and to invest further in one or more of Tern’s portfolio companies and for general corporate purposes.  Further announcements will be made by the Company in due course as appropriate.

CMC Markets UK Plc trading as CMC CapX, acted as the Company’s sole placing agent in respect of the Placing. 

Admission and Total Voting Rights

The Placing has been conducted utilising the Directors’ existing authorities to issue new Ordinary Shares.  The Placing Shares will rank pari passu in all respects with the existing Ordinary Shares.  The Placing is conditional, inter alia, on: i) there being no breach of the obligations under the Placing Agreement entered into between CMC Markets and the Company prior to Admission; and ii) Admission.  Application will be made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM.  It is expected that Admission will become effective and that dealings in the Placing Shares on AIM will commence on or around 18 April 2024.

In accordance with the Financial Conduct Authority’s Disclosure, Guidance and Transparency Rules, the Company confirms that following Admission, the Company’s enlarged issued ordinary share capital will comprise 427,176,311 Ordinary Shares. The Company does not hold any shares in Treasury.  Therefore, from Admission, the total number of voting rights in the Company will be 427,176,311 and this figure may be used by shareholders in the Company as the denominator for the calculations to determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure Guidance and Transparency Rules.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Search